CRISPR Therapeutics set for revenue growth as Casgevy launches in 2026 amid strong pipeline and partnerships.

CRISPR Therapeutics is expected to see significant revenue growth starting in 2026 with the launch of Casgevy, following FDA and EMA approvals for sickle cell disease and beta-thalassemia treatments. Despite strong efficacy and a promising pipeline, uptake has been slow due to challenging preconditioning and patient concerns. The stock is currently undervalued, trading at the low end of its four-year range, presenting a compelling buying opportunity. Strategic partnerships with Vertex, Sirius, and Eli Lilly further support CRISPR's growth potential.